Ms. Holmes and Mr. Balwani were found guilty of defrauding investors by falsely claiming Theranos’ technology could conduct fast, accurate blood tests with just a drop of blood. On Feb. 24, the appeals court ruled that their convictions were valid and that any minor legal errors during the 2022 trial did not affect the overall outcome. Becker’s obtained these court documents.
Ms. Holmes’ lawyers presented her appeal in a California federal appeals court June 11.
With their appeals rejected, Ms. Holmes and Mr. Balwani will remain in prison.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
